InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,567.19
(
1.06%
)
US TECH 100
19,830.00
(
0.96%
)
Dow Jones
39,375.87
(
0.17%
)
Brent Oil
86.78
(
-0.64%
)
Bitcoin
56,726.37
(
-0.45%
)
Post# of 252493
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119982
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: iwfal post# 252282

Friday, 06/21/2024 11:12:15 AM

Friday, June 21, 2024 11:12:15 AM

Post# of 252493
Re: OCUL competition

I don't expect gene therapy for AMD to gain much traction for the reasons you mentioned and, more fundamentally, because AMD is the kind of multifactorial disease that is inherently challenging for gene therapy.

I commented on this nine years ago in #msg-113278211; gene therapies have doubtless improved since then, but the issue still pertains, IMO.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up